H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $11 price target on Amyris, noting that the company announced it has entered into definitive agreements for the sale of $60M of unsecured convertible senior notes, in a private placement with two investors. Dayal said this financing removes an "important overhang" for the company, and believes that Amyris is now positioned to focus on execution during 2019. The analyst added that he is looking forward to more information from the company during the last three weeks of this year, including the announcement of a Chinese licensing agreement.